STERIS (NYSE:STE) Issues Earnings Results

STERIS (NYSE:STE) issued its quarterly earnings data on Wednesday. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01), Zacks reports. STERIS had a return on equity of 13.78% and a net margin of 8.02%. STERIS updated its FY 2025 guidance to 9.050-9.150 EPS.

STERIS Price Performance

NYSE:STE traded up $1.57 during mid-day trading on Wednesday, reaching $220.97. The stock had a trading volume of 887,926 shares, compared to its average volume of 476,648. STERIS has a one year low of $197.82 and a one year high of $248.24. The stock has a market capitalization of $21.81 billion, a P/E ratio of 50.45 and a beta of 0.84. The firm has a 50 day moving average price of $212.26 and a two-hundred day moving average price of $224.61. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be paid a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a yield of 1.03%. STERIS’s dividend payout ratio is presently 52.05%.

Wall Street Analysts Forecast Growth

Several research firms have commented on STE. Stephens reissued an “overweight” rating and set a $260.00 target price on shares of STERIS in a research report on Thursday, November 7th. Piper Sandler lifted their price target on STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday. JMP Securities restated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Finally, StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and a consensus price target of $263.75.

Insiders Place Their Bets

In other news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. This represents a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.14% of the stock is currently owned by insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.